Cargando…

A novel NET-related gene signature for predicting DLBCL prognosis

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy. Neutrophil extracellular traps (NETs) are pathogen-trapping structures in the tumor microenvironment that affect DLBCL progression. However, the predictive function of NET-related genes (NRGs) in DLBCL has received little...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Huizhong, Pan, Yiming, Xiang, Guifen, Wang, Mingwei, Huang, Yusong, He, Liu, Wang, Jue, Fang, Qian, Li, Ling, Liu, Zhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504796/ https://www.ncbi.nlm.nih.gov/pubmed/37716978 http://dx.doi.org/10.1186/s12967-023-04494-9

Ejemplares similares

Pretreatment Liver Injury Predicts Poor Prognosis of DLBCL Patients
por: Shi, Qing, et al.
Publicado: (2017)

Transformation of FL into DLBCL with a PMBL gene expression signature
por: Loveday, Tristan, et al.
Publicado: (2022)

The Immunology of DLBCL
por: Takahara, Taishi, et al.
Publicado: (2023)

IGFBP3 Enhances Treatment Outcome and Predicts Favorable Prognosis in ABC-DLBCL
por: Li, Han-Bing, et al.
Publicado: (2023)

P1247: IDENTIFICATION AND VERIFICATION OF IMMUNE-RELATED GENE PROGNOSTIC SIGNATURE BASED ON SSGSEA FOR DLBCL
por: Shi, Wenyu
Publicado: (2023)

Dysregulation of miRNAs in DLBCL: Causative Factor for Pathogenesis, Diagnosis and Prognosis
por: Alsaadi, Mohammed, et al.
Publicado: (2021)

HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy
por: Wan, Xin, et al.
Publicado: (2023)

Identification of Circulating Serum Multi-MicroRNA Signatures in Human DLBCL Models
por: Beheshti, Afshin, et al.
Publicado: (2019)

LASSO Model Better Predicted the Prognosis of DLBCL than Random Forest Model: A Retrospective Multicenter Analysis of HHLWG
por: Shen, Ziyuan, et al.
Publicado: (2022)

Check'-ing DLBCL
por: Salaverria, Itziar, et al.
Publicado: (2015)

DLBCL Coast to Coast
por: Tesio, Melania
Publicado: (2018)

GOALs in relapsed DLBCL
por: Rösler, Wiebke, et al.
Publicado: (2022)

CD5 and CD43 Expression are Associate with Poor Prognosis in DLBCL Patients
por: Huang, Hui, et al.
Publicado: (2018)

The immune checkpoint expression in the tumor immune microenvironment of DLBCL: Clinicopathologic features and prognosis
por: Ma, Jiajia, et al.
Publicado: (2022)

A germinal center–associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL
por: Miyawaki, Kohta, et al.
Publicado: (2022)

Identification of FAT4 as a positive prognostic biomarker in DLBCL by comprehensive genomic analysis
por: Lv, Liyang, et al.
Publicado: (2023)

A Novel Scoring System Based on the Level of HDL-C for Predicting the Prognosis of t-DLBCL Patients: A Single Retrospective Study
por: Xu, Jiadai, et al.
Publicado: (2018)

Identification of a 14-Gene Prognostic Signature for Diffuse Large B Cell Lymphoma (DLBCL)
por: Feng, Pengcheng, et al.
Publicado: (2021)

Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL
por: Mazzara, Saveria, et al.
Publicado: (2022)

Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study
por: Hawkes, Eliza A., et al.
Publicado: (2021)

DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set
por: Vrabac, Damir, et al.
Publicado: (2021)

CCND2 mRNA Expression Is Correlated With R-CHOP Treatment Efficacy and Prognosis in Patients With ABC-DLBCL
por: Wang, Di, et al.
Publicado: (2020)

A Novel Pyroptosis-Related Signature for Predicting Prognosis and Indicating Immune Microenvironment Features in Osteosarcoma
por: Zhang, Yiming, et al.
Publicado: (2021)

A Novel Defined PANoptosis-Related miRNA Signature for Predicting the Prognosis and Immune Characteristics in Clear Cell Renal Cell Carcinoma: A miRNA Signature for the Prognosis of ccRCC
por: Wang, Yanmei, et al.
Publicado: (2023)

Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma
por: Zhang, Mingwei, et al.
Publicado: (2020)

Cardiac Involvement by HIV-Associated DLBCL
por: Mupamombe, Charles T., et al.
Publicado: (2018)

The Tumor Microenvironment of DLBCL in the Computational Era
por: Opinto, Giuseppina, et al.
Publicado: (2020)

Neutrophil extracellular traps (NETs)-related lncRNAs signature for predicting prognosis and the immune microenvironment in breast cancer
por: Jiang, Tongchao, et al.
Publicado: (2023)

Sirt1 gene confers Adriamycin resistance in DLBCL via activating the PCG-1α mitochondrial metabolic pathway
por: Zhou, Zhen, et al.
Publicado: (2020)

RMTF-Net: Residual Mix Transformer Fusion Net for 2D Brain Tumor Segmentation
por: Gai, Di, et al.
Publicado: (2022)

Prognostic value of the baseline 18F-FDG PET/CT metabolic tumour volume (MTV) and further stratification in low-intermediate (L-I) and high-intermediate (H-I) risk NCCNIPI subgroup by MTV in DLBCL MTV predict prognosis in DLBCL
por: Zhao, Peng, et al.
Publicado: (2020)

Cuproptosis-related lncRNA signatures predict prognosis and immune relevance of kidney renal papillary cell carcinoma
por: Xie, Tongjin, et al.
Publicado: (2022)

Association of a novel seven-gene expression signature with the disease prognosis in colon cancer patients
por: Yang, Haojie, et al.
Publicado: (2019)

Prognosis and Tumour Immune Microenvironment of Patients With Hepatocellular Carcinoma by a Novel Pyroptosis-Related lncRNA Signature
por: Zhang, Ze, et al.
Publicado: (2022)

Comparison of MHG and DZsig reveals shared biology and a core overlap group with inferior prognosis in DLBCL
por: Davies, John R., et al.
Publicado: (2023)

PB2170: HIGH EXPRESSION OF AP2M1 CORRELATES WITH WORSE PROGNOSIS BY REGULATING IMMUNE MICROENVIRONMENT AND DRUG RESPONSE TO R-CHOP IN DLBCL
por: Liu, X.-D., et al.
Publicado: (2022)

Rituximab exposure‐response in triweekly R‐CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes
por: Liu, Shu, et al.
Publicado: (2021)

Attacking MALT1 for ABC-DLBCL therapy
por: Krappmann, Daniel
Publicado: (2012)

DUSP4 phosphatase puts the brakes on DLBCL
por: Rickert, Robert
Publicado: (2015)

CAR T-cell therapy for secondary CNS DLBCL
por: Ahmed, Gulrayz, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tr5iu1fi5qdqaove3c0f4m79kk